GlaxoSmithKline Pharmaceuticals SA
194.7 FTEGlaxoSmithKline Pharmaceuticals reported revenue of €241.2m for the 2025 financial year (non-consolidated annual accounts filed with the NBB on 03 Jul 2026), with 194.7 full-time equivalents.
The score of GlaxoSmithKline Pharmaceuticals shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +55 % Equity -77 % Total assets +21 % Headcount (avg FTE) +3 %
Accounts of the company itself (not consolidated). Consolidated group accounts are also filed: they are in the full file.
The full file covers 11 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
GlaxoSmithKline Pharmaceuticals's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 03 Jul 2026
- Year ended 31 Dec 2024filed on 04 Jul 2025
- Year ended 31 Dec 2023filed on 15 Jul 2024
- Year ended 31 Dec 2022filed on 11 Jul 2023
- Year ended 31 Dec 2021filed on 14 Jul 2022
GlaxoSmithKline Pharmaceuticals's financial analysis
- Solvency8.2%sector median: 43.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0403.066.474
- VAT number
- BE0403066474
- Peppol
- Registered · 0208:0403066474 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 01 Jan 1968
- Registered office
- 1300 Wavre
- Size
- Medium · 194.7 FTE
- Latest accounts
- 2025 · filed on 03 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
GlaxoSmithKline Pharmaceuticals (SA) has been based in Wavre since 1968, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports revenue of €241.2m, a net profit of €7.03m and equity of €4.78m. With 194.7 full-time equivalents, it is a medium-sized enterprise by headcount. Its solvency stands at 8.2%, below the median of its sector (43.9%).
Guide: Checking a Belgian supplier invoice: numbers and IBAN →
Companies similar to GlaxoSmithKline Pharmaceuticals
Companies in the same business, of comparable size and area, outside its group.
- V.M.D. Manufacture of pharmaceutical preparations Arendonk · balance sheet €28.5m
- KELA - Kempisch Laboratorium - Kela Laboratoria Manufacture of pharmaceutical preparations Hoogstraten · balance sheet €63.2m
- Eli Lilly European Clinical Trial Services Manufacture of medical and dental instruments and supplies Mont-Saint-Guibert · balance sheet €57.4m
- PHOENIX Pharma Belgium Manufacture of pharmaceutical preparations Woluwe-Saint-Lambert · balance sheet €235.4m
- Roche Manufacture of pharmaceutical preparations Anderlecht · balance sheet €164.7m
- BePharBel Manufacturing Manufacture of basic pharmaceutical products Courcelles · balance sheet €27.4m
- JNTL Consumer Health (Belgium) Manufacture of basic pharmaceutical products Antwerp · balance sheet €156.0m
- Odyssea Pharma Manufacture of pharmaceutical preparations Grâce-Hollogne · balance sheet €91.0m
Frequently asked questions about GlaxoSmithKline Pharmaceuticals
What is the revenue of GlaxoSmithKline Pharmaceuticals?
According to the 2025 annual accounts filed with the NBB, the revenue of GlaxoSmithKline Pharmaceuticals amounts to 241,221,934 €.
What is the VAT number of GlaxoSmithKline Pharmaceuticals?
In Belgium, the VAT number is the company number prefixed with BE: BE0403066474 for GlaxoSmithKline Pharmaceuticals, if the company is VAT-registered. Its company number (CBE) is 0403.066.474.
Where is the registered office of GlaxoSmithKline Pharmaceuticals?
According to the CBE register, the registered office of GlaxoSmithKline Pharmaceuticals is in 1300 Wavre.
What is the equity of GlaxoSmithKline Pharmaceuticals?
At the close of the 2025 financial year, the equity of GlaxoSmithKline Pharmaceuticals amounts to 4,778,595 €, a solvency of 8.2% of total assets.
How many people work at GlaxoSmithKline Pharmaceuticals?
194.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages GlaxoSmithKline Pharmaceuticals?
The register lists 2 active mandates at GlaxoSmithKline Pharmaceuticals. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of GlaxoSmithKline Pharmaceuticals
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →